Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct;22(10):1090-5.
doi: 10.1128/CVI.00375-15. Epub 2015 Aug 5.

Evaluation of the Specificity of Two Enzyme Immunoassays for Coccidioidomycosis by Using Sera from a Region of Endemicity and a Region of Nonendemicity

Affiliations

Evaluation of the Specificity of Two Enzyme Immunoassays for Coccidioidomycosis by Using Sera from a Region of Endemicity and a Region of Nonendemicity

Mark D Lindsley et al. Clin Vaccine Immunol. 2015 Oct.

Abstract

Coccidioidomycosis (CM), a serious life-threatening fungal infection endemic to arid regions of the western United States and Mexico, can be challenging to diagnose in a timely manner. Commercially developed enzyme immunoassays (EIAs) (from Meridian Biosciences and Immuno-Mycologics [IMMY]) have provided faster, simpler means for serodiagnosis; however, independent evaluations have questioned EIA specificity, particularly IgM-positive/IgG-negative results. This study was conducted to evaluate EIA specificity among persons residing in Puerto Rico (n = 534), where CM is not endemic (who were not likely to have been exposed to Coccidioides spp.), compared to blood bank donors residing in Arizona (n = 1,218), where CM is endemic. Upon comparing serum reactivity between Puerto Rico and Arizona, the Meridian EIA showed a significant difference in IgG reactivity (0.37% versus 3.6%; P < 0.001) but not IgM reactivity (3.4% versus 2.4%; P = 0.31). No IgM-/IgG-reactive sera were detected among sera from Puerto Rico, compared to 7 (0.57%) sera from Arizona. Similar results were observed using the IMMY EIA, although significantly (P = 0.03) fewer IgM-reactive sera from Arizona were observed, compared to the Meridian EIA. EIA-reactive sera were also evaluated by immunodiffusion before and after 3- to 4-fold concentration of the sera. These results demonstrate that elevated IgG EIA reactivity is present in sera from healthy individuals in regions of endemicity and that IgM EIA reactivity observed in sera from individuals residing outside regions of endemicity is most likely nonspecific. Other criteria, including clinical and microbiological evaluations, should be taken into account when interpreting results from surveillance studies and other reporting measures.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Levels of anti-Coccidioides IgM (filled symbols) and IgG (open symbols) measured by the Meridian EIA in 1,218 sera obtained from Arizona (AZ) and 534 sera obtained from Puerto Rico (PR). Shaded area, optical density range for indeterminate results. Sera with results above and below the indeterminate range are considered positive and negative, respectively, for antibodies against Coccidioides.
FIG 2
FIG 2
Levels of anti-Coccidioides IgM (filled symbols) and IgG (open symbols) measured by the IMMY EIA in 1,218 sera obtained from Arizona (AZ) and 534 sera obtained from Puerto Rico (PR). Shaded area, EIA unit range for indeterminate results. Sera with results above and below the indeterminate range are considered positive and negative, respectively, for antibodies against Coccidioides.

Similar articles

Cited by

References

    1. Nguyen C, Barker BM, Hoover S, Nix DE, Ampel NM, Frelinger JA, Orbach MJ, Galgiani JN. 2013. Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis. Clin Microbiol Rev 26:505–525. doi:10.1128/CMR.00005-13. - DOI - PMC - PubMed
    1. Thompson G III, Stevens D, Clemons K, Fierer J, Johnson R, Sykes J, Rutherford G, Peterson M, Taylor J, Chaturvedi V. 2015. Call for a California coccidioidomycosis consortium to face the top ten challenges posed by a recalcitrant regional disease. Mycopathologia 179:1–9. doi:10.1007/s11046-014-9816-7. - DOI - PubMed
    1. Crum N, Lederman E, Stafford C, Parrish JS, Wallace M. 2004. Coccidioidomycosis: a descriptive survey of a reemerging disease: clinical characteristics and current controversies. Medicine (Baltimore) 83:149–175. doi:10.1097/01.md.0000126762.91040.fd. - DOI - PubMed
    1. Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Johnson RH, Stevens DA, Williams PL. 2005. Coccidioidomycosis. Clin Infect Dis 41:1217–1223. doi:10.1086/496991. - DOI - PubMed
    1. Zartarian M, Peterson EM, de la Maza LM. 1997. Detection of antibodies to Coccidioides immitis by enzyme immunoassay. Am J Clin Pathol 107:148–153. - PubMed

Publication types